Pharmacological treatment for obesity; hormone therapy for postmenopausal women; and mepolizumab in patients with severe asthma… Debbie Rigby takes a look at the latest in research news
An umbrella review of 9 systematic reviews has concluded that liraglutide, orlistat, and naltrexone-bupropion are superior to placebo in reducing weight in adults. Orlistat was effective in significantly reducing fasting blood glucose, HbA1c, total cholesterol, triglycerides, and systolic and diastolic blood pressure.
Annals of Pharmacotherapy 2020.
Results from an Australian prospective cohort study show that women with premature menopause experince increased odds of developing chronic conditions and multimorbidity in their 60s. Strategies to reduce this risk include lifestyle change, controlling of body weight, metnally stimulating activity and regular screening for cancer and other reproductive conditions.
Human Reproduction 2020.
Women younger than 60 years of age or within 10 years after the onset of menopause who have symptomatic menopausal hot flashes or night sweats are most likely to benefit from hormone therapy. For women with early menopause without contraindications, hormone therapy is recommended until at least the average age of natural menopause. Observational studies suggest that the risk of thromboembolism and stroke is lower with transdermal therapy than with oral hormone therapy.
N Engl J Med 2020;382:446-55.
This retrospective cohort study (n=346) confirms the clinical benefit observed in previous mepolizumab clinical trials and demonstrates that mepolizumab is effective in a real-world setting. Mepolizumab, an anti-interleukin 5 monoclonal antibody indicated for severe eosinophilic asthma, reduced the rate of exacerbations and exacerbations requiring hospitalisation, and the use of oral and inhaled corticosteroids.
Journal of Asthma and Allergy 2020:13 77–87.